机构：[1]Shanghai East Hospital, Tongji University School of Medicine, Shanghai, PR China.[2]Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, PR China.[3]People's Liberation Army (PLA) Cancer Center, 81 Military Hospital of China, Nanjing, PR China.[4]Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, PR China.[5]Department of Medical Oncology, Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, PR China.[6]Department of Oncology, 307 Hospital of the Chinese People's Liberation Army, Beijing, PR China.[7]Department of Medical Oncology, West China Hospital of Sichuan University, Chengdu, PR China.四川大学华西医院[8]Department of Haematology-Oncology, National University Cancer Institute, Singapore.[9]Cancer Institute, Second Affiliated Hospital of Zhejiang University, Hangzhou, PR China.[10]Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, PR China.[11]Cancer Hospital, Harbin Medical University, Harbin, PR China.[12]Department of Medical Oncology, Fujian Province Cancer Hospital, Fuzhou, PR China.[13]Department of Medical Oncology, Kobe City Medical Center General Hospital, Hyogo, Japan.[14]Department of Oncology, National Taiwan University Cancer Center, National Taiwan University Hospital, Taipei, Taiwan.[15]Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, SAR.[16]Research and Development, Sanofi, Beijing, PR China.[17]Research and Development, Sanofi, Vitry-sur-Seine, France.[18]Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, PR China.
To investigate whether the benefit of combining aflibercept with 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) chemotherapy could be confirmed in patients from the Asia-Pacific region (ClinicalTrials.gov: NCT01661270). Patients & methods: Asian patients with oxaliplatin-pretreated metastatic colorectal cancer were randomized to receive aflibercept or placebo, followed by FOLFIRI. The primary end point was progression-free survival.
The intention-to-treat population comprised 332 patients. A clinical supply misallocation resulted in 198/332 (60%) patients receiving at least one cycle of misallocated treatment. Nevertheless, the addition of aflibercept to FOLFIRI was shown to improve progression-free survival (hazard ratio: 0.629; 95% CI: 0.488-0.812). Adverse events were in line with expectations.
The beneficial treatment effect associated with the addition of aflibercept to FOLFIRI was confirmed in Asian patients with pretreated metastatic colorectal cancer.
第一作者机构：[1]Shanghai East Hospital, Tongji University School of Medicine, Shanghai, PR China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Li Jin,Xu Ruihua,Qin Shukui,et al.Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study.[J].FUTURE ONCOLOGY.2018,14(20):2030-2043.doi:10.2217/fon-2017-0669.
APA：
Li Jin,Xu Ruihua,Qin Shukui,Liu Tianshu,Pan Hongming...&Shen Lin.(2018).Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study..FUTURE ONCOLOGY,14,(20)
MLA：
Li Jin,et al."Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study.".FUTURE ONCOLOGY 14..20(2018):2030-2043
